Pressure BioSciences (OTCQB: PBIO), a developer of innovative solutions for the worldwide life science and other industries, recently achieved another milestone as it nears initial production of commercial systems expected to revolutionize the nanoemulsification process for a wide variety of sectors. The company’s proprietary, next-generation Ultra Shear Technology-based BaroShear K45 System is designed to create unique, high-quality nanoemulsions of otherwise poorly soluble oils in order to render them more easily absorbed and effective in the water-based biology of human bodies. Pressure BioSciences earlier this year announced the launch of its UST Demonstration Laboratory as a place to showcase the technology’s potential to process cannabidiol (“CBD”) oil into true, high-quality, water-soluble nanoemulsions. PBIO reached sold-out status for its initial rollout of 12 planned BaroShear K45 systems. Then, on Oct. 6, the company announced the lock-in of final design specifications for the BaroShear K45’s commercial production model, which immediately launched work on construction of the initial K45 Alpha unit. Upon final completion, testing and approval of the Alpha unit, PBIO will build an additional 14 units, 12 of which are earmarked as ready-for-sale systems in time for the company to fulfill plans for shipping them during early 2021. An article discussing this quotes Pressure BioSciences’ director of marketing and sales, Kenneth F. Micciche. “Our commercialization plan for the BaroShear K45 system is initially focused on the rapidly growing hemp-derived CBD market, which is projected to reach $20 billion by 2020,” Micciche stated in a recent update. “We plan to install these (12 BaroShear K45 nanoemulsification) systems during the first half of 2021, which we believe will generate up to $3 million in revenue. Once these initial units are installed and in commercial use, we believe they will propel the close of multiple sales of additional BaroShear K45 systems during the latter half of 2021 and thereafter.”
To view the full article, visit https://ibn.fm/pnCRm
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life science and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher-quality, homogenized, extended shelf-life or room-temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
